- Home
- MBRX vs CING Comparison
MBRX vs CING Comparison
Compare MBRX & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBRX
- CING
- Stock Information
- Founded
- MBRX 2015
- CING 2012
- Country
- MBRX United States
- CING United States
- Employees
- MBRX N/A
- CING N/A
- Industry
- MBRX Biotechnology: Pharmaceutical Preparations
- CING Biotechnology: Pharmaceutical Preparations
- Sector
- MBRX Health Care
- CING Health Care
- Exchange
- MBRX Nasdaq
- CING Nasdaq
- Market Cap
- MBRX 11.3M
- CING 13.1M
- IPO Year
- MBRX 2016
- CING 2021
- Fundamental
- Price
- MBRX $1.11
- CING $4.34
- Analyst Decision
- MBRX Strong Buy
- CING Strong Buy
- Analyst Count
- MBRX 2
- CING 4
- Target Price
- MBRX $6.00
- CING $30.67
- AVG Volume (30 Days)
- MBRX 338.4K
- CING 96.1K
- Earning Date
- MBRX 05-09-2025
- CING 05-07-2025
- Dividend Yield
- MBRX N/A
- CING N/A
- EPS Growth
- MBRX N/A
- CING N/A
- EPS
- MBRX N/A
- CING N/A
- Revenue
- MBRX N/A
- CING N/A
- Revenue This Year
- MBRX N/A
- CING N/A
- Revenue Next Year
- MBRX N/A
- CING N/A
- P/E Ratio
- MBRX N/A
- CING N/A
- Revenue Growth
- MBRX N/A
- CING N/A
- 52 Week Low
- MBRX $0.40
- CING $1.80
- 52 Week High
- MBRX $5.47
- CING $20.83
- Technical
- Relative Strength Index (RSI)
- MBRX 58.77
- CING 58.78
- Support Level
- MBRX $0.80
- CING $4.03
- Resistance Level
- MBRX $1.05
- CING $4.44
- Average True Range (ATR)
- MBRX 0.10
- CING 0.30
- MACD
- MBRX 0.04
- CING 0.05
- Stochastic Oscillator
- MBRX 100.00
- CING 77.69
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.